SCHEMBL667725

SCHEMBL667725

CCCCCS(=O)(=O)N[C]=O

nearest known ligand 0.43

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.43
RELA Q04206 4/20 0.40
CA2 P00918 2/20 0.39
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
CA1 P00915 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7522852 0.98 FAAH (0.46) FAAHRELACA2MEN1ALDH1A1
SCHEMBL8637397 0.98 FAAH (0.46) FAAHRELACA2MEN1ALDH1A1
SCHEMBL4910681 0.98 FAAH (0.46) FAAHRELACA2MEN1ALDH1A1
SCHEMBL966696 0.98 FAAH (0.46) FAAHRELACA2MEN1ALDH1A1
SCHEMBL1751774 0.98 FAAH (0.46) FAAHRELACA2MEN1ALDH1A1
SCHEMBL424437 0.93 CA1 (0.38) FAAHRELACA2MEN1ALDH1A1
SCHEMBL423936 0.83
SCHEMBL27884330 0.80 FAAH (0.41) FAAHRELACA2CA1
SCHEMBL5313006 0.80 FAAH (0.41) FAAHRELACA2CA1
SCHEMBL5532020 0.76 CA2 (0.48) FAAHRELACA2MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004181-B3 ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES UNIV CALIFORNIA (US) 2023-05-24 EP claimed
EP-2004181-B1 ANDROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND ANDROGEN RECEPTOR-ASSOCIATED DISEASES UNIV CALIFORNIA (US) 2016-02-24 EP claimed
CN-103554006-A Use of indole derivatives as nurr-1 activators for the application thereof as a medicament for the treatment of parkinson's disease FOURNIER LAB SA 2014-02-05 CN claimed
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 US claimed
EP-2475642-A1 USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE Laboratoires Fournier S.A. (FR) 2012-07-18 EP claimed
CN-102596906-A Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease FOURNIER LAB SA 2012-07-18 CN claimed
CN-102236257-A Coloring photosensitive composition, manufacture method for color filter, color filter, and liquid crystal display device FUJI PHOTO FILM CO LTD 2011-11-09 CN claimed
WO-2011030068-A1 USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE LABORATOIRES FOURNIER SA (FR) 2011-03-17 WO claimed
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 US claimed
US-20100190830-A1 (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2010-07-29 US claimed
CN-1446200-A Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-ichibiting anti-inflammatory and immune-suppressive agents ABBOTT LAB (US) 2003-10-01 CN claimed
US-20030181496-A1 Pyrrole derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2003-09-25 US claimed
EP-0946202-B1 CONTRAST AGENTS AMERSHAM HEALTH AS (NO) 2003-09-10 EP claimed
CN-1100777-C N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2003-02-05 CN claimed
CN-1353691-A Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds ABBOTT LAB (US) 2002-06-12 CN claimed
CN-1350520-A Anti-inflammatory and immunosuppressive cell adhesion inhibiting compounds ABBOTT LAB (US) 2002-05-22 CN claimed
CN-1252799-A N-heterocyclic derivatives as NOS inhibitor BERLEX LAB (US) 2000-05-10 CN claimed
US-5306609-A With nondiffusive coupler and acyl acetamide coupler of specified formulae; high color density, color image fastness FUJI PHOTO FILM CO., LTD. (JP) 1994-04-26 US claimed
CN-1081438-A Imdazole derivatives and preparation method thereof and the application on therapeutics FOURNIER IND & SANTE (FR) 1994-02-02 CN claimed
US-4640940-A CONTACT LENSES LOCTITE CORPORATION (US) 1987-02-03 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A FAAH 3040/4885RELA 435/4885CA2 4693/4885
US-20100190830-A1 (3-Amino-1,2,3,4-Tetrahydro-9H-Carbazol-9-yl)-Acetic Acid Derivatives PTGDR, PTGER1, PTGIR FAAH 251/4885RELA 771/4885CA2 810/4885
US-20030181496-A1 Pyrrole derivatives NCOA1, PKD1, NR3C2 FAAH 1975/4885RELA 1000/4885CA2 1415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.